A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors

Johanna C. BendellSarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee, USACorrespondence[email protected]

Suzanne F. JonesSarah Cannon Research Institute, Nashville, Tennessee, USA

Lowell HartFlorida Cancer Specialists/SCRI, Ft. Myers, Florida, USA

Shubham PantOklahoma University/SCRI, Oklahoma City, Oklahoma, USA

Adil MoyhuddinTennessee Oncology, PLLC/SCRI, Nashville, Tennessee, USA

Cassie M. LaneSarah Cannon Research Institute, Nashville, Tennessee, USA

Chris EarwoodSarah Cannon Research Institute, Nashville, Tennessee, USA

Patrick MurphyTennessee Oncology, PLLC/SCRI, Nashville, Tennessee, USA

Jeffrey PattonTennessee Oncology, PLLC/SCRI, Nashville, Tennessee, USA

William C. PenleyTennessee Oncology, PLLC/SCRI, Nashville, Tennessee, USA

Dana ThompsonTennessee Oncology, PLLC/SCRI, Nashville, Tennessee, USA

Jeffrey R. InfanteTennessee Oncology, PLLC/SCRI, Nashville, Tennessee, USA

Your download is now in progress and you may close this window